https://www.pharmaceutical-technology.com/data-insights/zw-171-zymeworks-colorectal-cancer-likelihood-of-approval/ 2024-12-30T18:51:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nexiguran-ziclumeran-regeneron-pharmaceuticals-familial-amyloid-cardiomyopathy-likelihood-of-approval/ 2024-12-30T18:51:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mosliciguat-bayer-kidney-disease-nephropathy-likelihood-of-approval/ 2024-12-30T18:51:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vactosertib-medpacto-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-30T18:51:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abemaciclib-eli-lilly-and-co-adipocytic-sarcoma-likelihood-of-approval/ 2024-12-30T18:51:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talditercept-alfa-biohaven-unspecified-metabolic-disorders-likelihood-of-approval/ 2024-12-30T18:51:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ascrinvacumab-kintor-pharmaceutical-liver-cancer-likelihood-of-approval/ 2024-12-30T18:51:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-paranasal-sinus-and-nasal-cavity-cancer-likelihood-of-approval/ 2024-12-30T18:51:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/es-4000-escend-pharmaceuticals-metastatic-breast-cancer-likelihood-of-approval/ 2024-12-30T18:51:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nuc-7738-nucana-t-cell-lymphomas-likelihood-of-approval/ 2024-12-30T18:51:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nlx-101-neurolixis-fragile-x-syndrome-likelihood-of-approval/ 2024-12-30T18:51:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-145-merus-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval/ 2024-12-30T18:51:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zw-191-zymeworks-endometrial-cancer-likelihood-of-approval/ 2024-12-30T18:50:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tigilanol-tiglate-qbiotics-group-fibrosarcoma-likelihood-of-approval/ 2024-12-30T18:50:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-12-30T18:50:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-renal-cell-carcinoma-likelihood-of-approval/ 2024-12-30T18:50:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sage-689-sage-therapeutics-unspecified-central-nervous-system-disorders-likelihood-of-approval/ 2024-12-30T18:50:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emavusertib-hydrochloride-curis-primary-cns-lymphoma-likelihood-of-approval/ 2024-12-30T18:50:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wp-1066-moleculin-biotech-brain-tumor-likelihood-of-approval/ 2024-12-30T18:50:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T18:50:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/annexuzlimab-medannex-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T18:50:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wp-1066-moleculin-biotech-metastatic-melanoma-likelihood-of-approval/ 2024-12-30T18:50:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/das-181-ansun-biopharma-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T18:50:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zelpultide-alfa-airway-therapeutics-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T18:50:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lixumistat-immunomet-therapeutics-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2024-12-30T18:50:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-solid-tumor-likelihood-of-approval/ 2024-12-30T18:50:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wp-1066-moleculin-biotech-pediatric-diffuse-intrinsic-pontine-glioma-likelihood-of-approval/ 2024-12-30T18:50:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brimarafenib-mapkure-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T18:50:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-head-and-neck-cancer-likelihood-of-approval/ 2024-12-30T18:49:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/q-901-qurient-metastatic-ovarian-cancer-likelihood-of-approval/ 2024-12-30T18:49:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilparencel-prokidney-diabetic-nephropathy-likelihood-of-approval/ 2024-12-30T18:49:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lacripep-tearsolutions-sicca-syndrome-sjogren-likelihood-of-approval/ 2024-12-30T18:49:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/soticlestat-takeda-pharmaceutical-epileptic-encephalopathy-likelihood-of-approval/ 2024-12-30T18:49:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilparencel-prokidney-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2024-12-30T18:49:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/com-701-compugen-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T18:49:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ion-464-ionis-pharmaceuticals-parkinson-s-disease-likelihood-of-approval/ 2024-12-30T18:49:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tapotoclax-amgen-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T18:49:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/valemetostat-daiichi-sankyo-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2024-12-30T18:49:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dpxe-7-biovaxys-technology-anal-cancer-likelihood-of-approval/ 2024-12-30T18:49:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wven-531-wave-life-sciences-duchenne-muscular-dystrophy-likelihood-of-approval/ 2024-12-30T18:49:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/doxorubicin-hydrochloride-skinject-basal-cell-carcinoma-basal-cell-epithelioma-likelihood-of-approval/ 2024-12-30T18:49:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dpxe-7-biovaxys-technology-head-and-neck-cancer-likelihood-of-approval/ 2024-12-30T18:49:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/poly-iclc-oncovir-melanoma-likelihood-of-approval/ 2024-12-30T18:49:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/centhaquine-citrate-pharmazz-acute-renal-failure-arf-acute-kidney-injury-likelihood-of-approval/ 2024-12-30T18:49:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/capsulin-oad-diabetology-products-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/ 2024-12-30T18:48:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/benzgalantamine-dr-alphacognition-traumatic-brain-injury-likelihood-of-approval/ 2024-12-30T18:48:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vactosertib-medpacto-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T18:48:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nt-219-purple-biotech-solid-tumor-likelihood-of-approval/ 2024-12-30T18:48:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nuc-7738-nucana-chordoma-likelihood-of-approval/ 2024-12-30T18:48:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adpa-2afp-adaptimmune-therapeutics-neuroendocrine-tumors-likelihood-of-approval/ 2024-12-30T18:48:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dalpiciclib-jiangsu-hengrui-medicine-metastatic-ovarian-cancer-likelihood-of-approval/ 2024-12-30T18:48:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cyp-001-cynata-therapeutics-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2024-12-30T18:48:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sodium-phenylbutyrate-taurursodiol-amylyx-pharmaceuticals-mild-cognitive-impairment-likelihood-of-approval/ 2024-12-30T18:48:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sion-2851-sionna-therapeutics-cystic-fibrosis-likelihood-of-approval/ 2024-12-30T18:48:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vs-105-vidasym-osteoporosis-likelihood-of-approval/ 2024-12-30T18:48:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tazemetostat-hydrobromide-ipsen-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-30T18:48:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-biosimilar-essex-bio-technology-wet-neovascular-exudative-macular-degeneration-likelihood-of-approval/ 2024-12-30T18:48:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vactosertib-medpacto-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-30T18:48:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-145-merus-oropharyngeal-cancer-likelihood-of-approval/ 2024-12-30T18:48:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efineptakin-alfa-neoimmunetech-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T18:48:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sodium-oxybate-er-avadel-pharmaceuticals-idiopathic-hypersomnia-ih-likelihood-of-approval/ 2024-12-30T18:48:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-145-merus-unspecified-b-cell-lymphomas-likelihood-of-approval/ 2024-12-30T18:48:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evorpacept-alx-oncology-refractory-multiple-myeloma-likelihood-of-approval/ 2024-12-30T18:47:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ketoprofen-achelios-therapeutics-arthralgia-joint-pain-likelihood-of-approval/ 2024-12-30T18:47:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vb-1016-nykode-therapeutics-cervical-cancer-likelihood-of-approval/ 2024-12-30T18:47:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rslv-132-resolve-therapeutics-primary-sjogren-s-syndrome-likelihood-of-approval/ 2024-12-30T18:47:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-metastatic-prostate-cancer-likelihood-of-approval/ 2024-12-30T18:47:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/phentolamine-mesylate-opus-genetics-presbyopia-likelihood-of-approval/ 2024-12-30T18:47:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/futibatinib-otsuka-pharmaceutical-esophageal-cancer-likelihood-of-approval/ 2024-12-30T18:47:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-bladder-cancer-likelihood-of-approval/ 2024-12-30T18:47:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/durvalumab-astrazeneca-salivary-gland-cancer-likelihood-of-approval/ 2024-12-30T18:47:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitoxantrone-hydrochloride-cspc-pharmaceutical-group-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2024-12-30T18:47:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-soft-tissue-sarcoma-likelihood-of-approval/ 2024-12-30T18:47:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-anaplastic-thyroid-cancer-likelihood-of-approval/ 2024-12-30T18:47:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fenfluramine-hydrochloride-ucb-unspecified-genetic-disorders-likelihood-of-approval/ 2024-12-30T18:47:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/furosemide-scpharmaceuticals-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2024-12-30T18:47:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-30T18:47:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/durvalumab-astrazeneca-neuroendocrine-carcinoma-likelihood-of-approval/ 2024-12-30T18:47:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-colon-cancer-likelihood-of-approval/ 2024-12-30T18:46:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-mantle-cell-lymphoma-likelihood-of-approval/ 2024-12-30T18:46:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pneumonia-vaccine-sk-bioscience-pneumonia-likelihood-of-approval/ 2024-12-30T18:46:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hpv-16-e7-gilead-sciences-human-papillomavirus-hpv-associated-cancer-likelihood-of-approval/ 2024-12-30T18:46:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/calquence-astrazeneca-anti-mag-peripheral-neuropathy-likelihood-of-approval/ 2024-12-30T18:46:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/com-701-compugen-fallopian-tube-cancer-likelihood-of-approval/ 2024-12-30T18:46:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-biosimilar-r-pharm-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T18:46:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/firicabtagene-autoleucel-cargo-therapeutics-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-30T18:46:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sirolimus-biodexa-pharmaceuticals-prostate-cancer-likelihood-of-approval-2/ 2024-12-30T18:45:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/sirolimus-biodexa-pharmaceuticals-prostate-cancer-likelihood-of-approval/ 2024-12-30T18:44:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/influenza-types-a-and-b-quadrivalent-vaccine-csl-unspecified-influenza-virus-infections-likelihood-of-approval/ 2024-12-30T18:44:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sx-682-syntrix-pharmaceuticals-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-12-30T18:35:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/calquence-astrazeneca-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T18:35:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trilaciclib-pharmacosmos-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T18:35:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/com-701-compugen-paranasal-sinus-and-nasal-cavity-cancer-likelihood-of-approval/ 2024-12-30T18:35:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lisocabtagene-maraleucel-bristol-myers-squibb-unspecified-b-cell-lymphomas-likelihood-of-approval/ 2024-12-30T18:35:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/delgocitinib-leo-pharma-hand-dermatitis-likelihood-of-approval/ 2024-12-30T18:35:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sp-420-pharmacosmos-beta-thalassaemia-likelihood-of-approval/ 2024-12-30T18:35:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crd-1-merck-myasthenia-gravis-likelihood-of-approval/ 2024-12-30T18:35:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sovleplenib-acetate-hutchison-medipharma-idiopathic-thrombocytopenic-purpura-immune-thrombocytopenic-purpura-likelihood-of-approval/ 2024-12-30T18:35:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stenoparib-allarity-therapeutics-breast-cancer-likelihood-of-approval/ 2024-12-30T18:35:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemarituzumab-amgen-bladder-cancer-likelihood-of-approval/ 2024-12-30T18:35:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gnt-0003-genethon-crigler-najjar-syndrome-likelihood-of-approval/ 2024-12-30T18:35:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/com-701-compugen-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T18:34:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/com-701-compugen-colorectal-cancer-likelihood-of-approval/ 2024-12-30T18:34:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fosfomycin-disodium-meitheal-pharmaceuticals-urinary-tract-infections-likelihood-of-approval/ 2024-12-30T18:34:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/calquence-astrazeneca-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T18:34:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rogaratinib-bayer-solid-tumor-likelihood-of-approval/ 2024-12-30T18:34:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/g-100-merck-soft-tissue-sarcoma-likelihood-of-approval/ 2024-12-30T18:34:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/monepantel-neurizon-therapeutics-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2024-12-30T18:34:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vactosertib-medpacto-acute-lymphoblastic-lymphoma-likelihood-of-approval/ 2024-12-30T18:34:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lucicebtide-sapience-therapeutics-signet-ring-cell-squamous-cell-carcinoma-likelihood-of-approval/ 2024-12-30T18:34:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cefepime-zidebactam-wockhardt-meningitis-likelihood-of-approval/ 2024-12-30T18:34:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/teriparatide-biosimilar-tsh-biopharm-osteoporosis-likelihood-of-approval/ 2024-12-30T18:34:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sovleplenib-acetate-hutchison-medipharma-mantle-cell-lymphoma-likelihood-of-approval/ 2024-12-30T18:34:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kh-903-chengdu-kanghong-pharmaceuticals-group-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T18:34:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/isunakinra-buzzard-pharmaceuticals-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-30T18:34:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sulodexide-alfasigma-venous-thromboembolism-likelihood-of-approval/ 2024-12-30T18:33:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/granexin-xequel-bio-radiodermatitis-likelihood-of-approval/ 2024-12-30T18:33:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oryn-1001-oryn-therapeutics-rheumatoid-arthritis-likelihood-of-approval/ 2024-12-30T18:33:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gd2-cart01-bellicum-pharmaceuticals-pediatric-diffuse-intrinsic-pontine-glioma-likelihood-of-approval/ 2024-12-30T18:33:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gd2-cart01-bellicum-pharmaceuticals-high-grade-glioma-likelihood-of-approval/ 2024-12-30T18:33:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tigilanol-tiglate-qbiotics-group-merkel-cell-carcinoma-likelihood-of-approval/ 2024-12-30T18:33:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xp-105-xynomic-pharmaceuticals-breast-cancer-likelihood-of-approval/ 2024-12-30T18:33:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/citarinostat-bristol-myers-squibb-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-12-30T18:33:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wp-1066-moleculin-biotech-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T18:33:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nanvuranlat-j-pharma-colorectal-cancer-likelihood-of-approval/ 2024-12-30T18:33:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sumecigrel-jiangsu-vcare-pharmatech-acute-coronary-syndrome-likelihood-of-approval/ 2024-12-30T18:33:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nadunolimab-cantargia-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-12-30T18:33:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rimegepant-sulfate-odt-pfizer-plaque-psoriasis-psoriasis-vulgaris-likelihood-of-approval/ 2024-12-30T18:33:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vs-01-genfit-acute-on-chronic-liver-failure-aclf-likelihood-of-approval/ 2024-12-30T18:32:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/belrestotug-iteos-therapeutics-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T18:32:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zen-3694-zenith-epigenetics-unspecified-b-cell-lymphomas-likelihood-of-approval/ 2024-12-30T18:32:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vorbipiprant-sodium-rottapharm-biotech-gastrointestinal-tumor-likelihood-of-approval/ 2024-12-30T18:32:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vorbipiprant-sodium-rottapharm-biotech-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-12-30T18:32:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paltusotine-hydrochloride-crinetics-pharmaceuticals-acromegaly-likelihood-of-approval/ 2024-12-30T18:32:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bisantrene-race-oncology-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T18:32:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tak-243-millennium-pharmaceuticals-lymphoma-likelihood-of-approval/ 2024-12-30T18:32:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evorpacept-alx-oncology-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-12-30T18:32:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aminolevulinic-acid-hydrochloride-photonamic-meningioma-likelihood-of-approval/ 2024-12-30T18:32:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tinostamustine-mundipharma-edo-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T18:32:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asengeprast-certa-therapeutics-systemic-sclerosis-scleroderma-likelihood-of-approval/ 2024-12-30T18:32:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eltanexor-karyopharm-therapeutics-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T18:32:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/retifanlimab-incyte-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2024-12-30T18:31:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tenalisib-rhizen-pharmaceuticals-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T18:31:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-dae-hwa-pharmaceutical-cervical-cancer-likelihood-of-approval/ 2024-12-30T18:31:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fb-825-oneness-biotech-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-12-30T18:31:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tazemetostat-hydrobromide-ipsen-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T18:31:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navtemadlin-kartos-therapeutics-liposarcoma-likelihood-of-approval/ 2024-12-30T18:31:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evalstotug-bioatla-solid-tumor-likelihood-of-approval/ 2024-12-30T18:31:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/deucravacitinib-bristol-myers-squibb-unspecified-dermatological-disorders-likelihood-of-approval/ 2024-12-30T18:31:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-neuroendocrine-tumors-likelihood-of-approval/ 2024-12-30T18:31:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-ureter-cancer-likelihood-of-approval/ 2024-12-30T18:31:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/com-701-compugen-ovarian-cancer-likelihood-of-approval/ 2024-12-30T18:31:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/com-701-compugen-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T18:31:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zamaporvint-redx-pharma-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T18:31:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avadomide-hydrochloride-bristol-myers-squibb-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T18:30:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incvax-immunophotonics-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-30T18:30:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cwp-291-jw-pharmaceutical-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T18:30:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/q-901-qurient-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T18:30:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ovx-836-osivax-unspecified-influenza-virus-infections-likelihood-of-approval/ 2024-12-30T18:30:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sumecigrel-jiangsu-vcare-pharmatech-ischemic-stroke-likelihood-of-approval/ 2024-12-30T18:30:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dalcinonacog-alfa-la-gyre-therapeutics-hemophilia-b-factor-ix-deficiency-likelihood-of-approval/ 2024-12-30T18:30:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/deucravacitinib-bristol-myers-squibb-rosacea-likelihood-of-approval/ 2024-12-30T18:30:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tirzepatide-eli-lilly-and-co-obesity-likelihood-of-approval/ 2024-12-30T18:30:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-bladder-cancer-likelihood-of-approval/ 2024-12-30T18:30:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plixorafenib-fore-biotherapeutics-glioma-likelihood-of-approval/ 2024-12-30T18:30:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aldesleukin-iltoo-pharma-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2024-12-30T18:30:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nt-219-purple-biotech-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T18:30:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tba-7371-astrazeneca-pulmonary-tuberculosis-likelihood-of-approval/ 2024-12-30T18:29:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/levi-04-levicept-osteoarthritis-pain-likelihood-of-approval/ 2024-12-30T18:29:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plx-038-prolynx-paraplegia-likelihood-of-approval/ 2024-12-30T18:29:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dordaviprone-hydrochloride-chimerix-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-12-30T18:29:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mesenchymal-stromal-cell-therapy-orbsen-therapeutics-rheumatoid-arthritis-likelihood-of-approval/ 2024-12-30T18:29:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ianalumab-novartis-rheumatoid-arthritis-likelihood-of-approval/ 2024-12-30T18:29:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/entrectinib-f-hoffmann-la-roche-high-grade-glioma-likelihood-of-approval/ 2024-12-30T18:29:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/larotrectinib-sulfate-bayer-thyroid-cancer-likelihood-of-approval/ 2024-12-30T18:29:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plx-038-prolynx-central-nervous-system-cns-tumor-likelihood-of-approval/ 2024-12-30T18:26:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/futibatinib-otsuka-pharmaceutical-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2024-12-30T18:26:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avelumab-merck-natural-killer-cell-lymphomas-likelihood-of-approval/ 2024-12-30T18:26:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olanzapine-samidorphan-l-malate-alkermes-bipolar-i-disorder-likelihood-of-approval/ 2024-12-30T18:26:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cinrebafusp-alfa-pieris-pharmaceuticals-esophageal-cancer-likelihood-of-approval/ 2024-12-30T18:26:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cinrebafusp-alfa-pieris-pharmaceuticals-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T18:26:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cinrebafusp-alfa-pieris-pharmaceuticals-colorectal-cancer-likelihood-of-approval/ 2024-12-30T18:26:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/larotrectinib-sulfate-bayer-salivary-gland-cancer-likelihood-of-approval/ 2024-12-30T18:26:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lv-305-merck-myxoid-liposarcoma-likelihood-of-approval/ 2024-12-30T18:26:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2024-12-30T18:26:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T18:26:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pimitespib-otsuka-pharmaceutical-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T18:25:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navtemadlin-kartos-therapeutics-metastatic-breast-cancer-likelihood-of-approval/ 2024-12-30T18:25:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rslv-132-resolve-therapeutics-systemic-lupus-erythematosus-likelihood-of-approval/ 2024-12-30T18:25:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T18:25:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navtemadlin-kartos-therapeutics-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T18:25:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fosmanogepix-basilea-pharmaceutica-aspergillosis-likelihood-of-approval/ 2024-12-30T18:25:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gemcabene-neurobo-pharmaceuticals-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2024-12-30T18:25:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trn-157-theron-pharmaceuticals-chronic-obstructive-pulmonary-disease-copd-likelihood-of-approval/ 2024-12-30T18:25:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inobrodib-cellcentric-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-12-30T18:25:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lae-001-laekna-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-30T18:25:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tigilanol-tiglate-qbiotics-group-adenocarcinoma-likelihood-of-approval/ 2024-12-30T18:25:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tigilanol-tiglate-qbiotics-group-basal-cell-carcinoma-basal-cell-epithelioma-likelihood-of-approval/ 2024-12-30T18:25:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-30T18:25:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T18:25:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/calpurbatug-trellis-bioscience-prosthetic-joint-infections-likelihood-of-approval/ 2024-12-30T18:24:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itacitinib-adipate-incyte-myelodysplastic-syndrome-likelihood-of-approval/ 2024-12-30T18:24:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cr-9114-leyden-laboratories-influenza-a-virus-h3n2-subtype-infections-likelihood-of-approval/ 2024-12-30T18:24:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selinexor-karyopharm-therapeutics-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T18:24:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/calpurbatug-trellis-bioscience-gram-negative-bacterial-infections-likelihood-of-approval/ 2024-12-30T18:24:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/calpurbatug-trellis-bioscience-gram-positive-bacterial-infections-likelihood-of-approval/ 2024-12-30T18:24:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rvu-120-ryvu-therapeutics-anemia-likelihood-of-approval/ 2024-12-30T18:24:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/immune-globulin-human-octapharma-unspecified-neurologic-disorders-likelihood-of-approval/ 2024-12-30T18:24:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nnz-2591-neuren-pharmaceuticals-angelman-syndrome-likelihood-of-approval/ 2024-12-30T18:24:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-urethral-cancer-likelihood-of-approval/ 2024-12-30T18:24:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanubrutinib-beigene-unspecified-b-cell-lymphomas-likelihood-of-approval/ 2024-12-30T18:24:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T18:24:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zw-191-zymeworks-solid-tumor-likelihood-of-approval/ 2024-12-30T18:24:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ritivixibat-ipsen-liver-diseases-likelihood-of-approval/ 2024-12-30T18:23:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pruxelutamide-kintor-pharmaceutical-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T18:23:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/veliparib-er-abbvie-essential-thrombocythemia-likelihood-of-approval/ 2024-12-30T18:23:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/veliparib-er-abbvie-polycythemia-vera-likelihood-of-approval/ 2024-12-30T18:23:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/calquence-astrazeneca-follicular-lymphoma-likelihood-of-approval/ 2024-12-30T18:23:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stenoparib-allarity-therapeutics-endometrial-cancer-likelihood-of-approval/ 2024-12-30T18:23:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/isunakinra-buzzard-pharmaceuticals-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T18:23:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/isunakinra-buzzard-pharmaceuticals-solid-tumor-likelihood-of-approval/ 2024-12-30T18:23:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xofluza-shionogi-unspecified-influenza-virus-infections-likelihood-of-approval/ 2024-12-30T18:23:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmn-005-benecyte-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T18:23:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmn-005-benecyte-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T18:23:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anifrolumab-astrazeneca-subacute-cutaneous-lupus-erythematosus-scle-likelihood-of-approval/ 2024-12-30T18:23:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/resomelagon-synact-pharma-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2024-12-30T18:23:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/calquence-astrazeneca-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval/ 2024-12-30T18:23:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/debio-0123-debiopharm-international-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T18:22:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmn-005-benecyte-follicular-lymphoma-likelihood-of-approval/ 2024-12-30T18:22:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vorasidenib-citrate-les-laboratoires-servier-solid-tumor-likelihood-of-approval/ 2024-12-30T18:22:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lutikizumab-abbvie-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2024-12-30T18:22:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sb-011-sterna-biologicals-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-12-30T18:22:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nelonemdaz-gnt-pharma-acute-ischemic-stroke-likelihood-of-approval/ 2024-12-30T18:22:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lumateperone-tosylate-intra-cellular-therapies-autism-spectrum-disorder-asd-likelihood-of-approval/ 2024-12-30T18:22:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bio-11006-biomarck-pharmaceuticals-ewing-sarcoma-likelihood-of-approval/ 2024-12-30T18:22:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aldesleukin-iltoo-pharma-allergic-rhino-conjunctivitis-likelihood-of-approval/ 2024-12-30T18:22:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gammora-zion-medical-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2024-12-30T18:22:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceralasertib-astrazeneca-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-30T18:22:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paxalisib-kazia-therapeutics-gliosarcoma-likelihood-of-approval/ 2024-12-30T18:22:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lifileucel-iovance-biotherapeutics-endometrial-cancer-likelihood-of-approval/ 2024-12-30T18:22:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nuc-7738-nucana-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-30T18:22:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mevidalen-hydroxybenzoate-eli-lilly-and-co-alzheimer-s-disease-likelihood-of-approval/ 2024-12-30T18:21:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mumo-1-esteve-pharmaceuticals-unspecified-pain-likelihood-of-approval/ 2024-12-30T18:21:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ea-230-exponential-biotherapies-acute-inflammation-likelihood-of-approval/ 2024-12-30T18:21:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lg-631-lentigen-technology-gliosarcoma-likelihood-of-approval/ 2024-12-30T18:21:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/thrombomodulin-alfa-asahi-kasei-pharma-chemotherapy-induced-peripheral-neuropathy-likelihood-of-approval/ 2024-12-30T18:21:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irl-201104-revolo-biotherapeutics-inflammation-likelihood-of-approval/ 2024-12-30T18:21:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-dae-hwa-pharmaceutical-head-and-neck-cancer-likelihood-of-approval/ 2024-12-30T18:21:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/q-901-qurient-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-30T18:21:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rucaparib-camsylate-pharmaand-endometrial-cancer-likelihood-of-approval/ 2024-12-30T18:21:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/creavax-hcc-jw-creagene-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-30T18:21:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-30T18:21:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-12-30T18:21:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anakinra-swedish-orphan-biovitrum-sepsis-likelihood-of-approval/ 2024-12-30T18:21:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-145-merus-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-30T18:21:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-145-merus-bladder-cancer-likelihood-of-approval/ 2024-12-30T18:20:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dostarlimab-gsk-adrenocortical-carcinoma-adrenal-cortex-cancer-likelihood-of-approval/ 2024-12-30T18:20:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/creavax-ra-jw-creagene-rheumatoid-arthritis-likelihood-of-approval/ 2024-12-30T18:20:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/q-901-qurient-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-30T18:20:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/q-901-qurient-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T18:20:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibudilast-medicinova-chemotherapy-induced-peripheral-neuropathy-likelihood-of-approval/ 2024-12-30T18:20:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/valiltramiprosate-alzheon-down-syndrome-likelihood-of-approval/ 2024-12-30T18:20:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tigilanol-tiglate-qbiotics-group-adenoid-cystic-carcinoma-acc-likelihood-of-approval/ 2024-12-30T18:20:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erc-1671-erc-belgium-gliosarcoma-likelihood-of-approval/ 2024-12-30T18:20:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sovleplenib-acetate-hutchison-medipharma-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T18:20:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erfonrilimab-alphamab-oncology-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T18:20:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-gastrointestinal-tract-cancer-likelihood-of-approval/ 2024-12-30T18:20:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-588-biotest-community-acquired-pneumonia-likelihood-of-approval/ 2024-12-30T18:20:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vcn-01-theriva-biologics-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2024-12-30T18:19:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cusatuzumab-oncoverity-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-12-30T18:19:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ruxolitinib-phosphate-novartis-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T18:19:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brilacidin-innovation-pharmaceuticals-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T18:19:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/q-901-qurient-endometrial-cancer-likelihood-of-approval/ 2024-12-30T18:19:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snt-5382-syntara-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2024-12-30T18:19:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mesenchymal-stromal-cell-therapy-orbsen-therapeutics-lupus-nephritis-likelihood-of-approval/ 2024-12-30T18:19:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sovleplenib-acetate-hutchison-medipharma-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2024-12-30T18:19:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bupivacaine-hydrochloride-oncozenge-oral-mucositis-likelihood-of-approval/ 2024-12-30T18:19:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-dae-hwa-pharmaceutical-bladder-cancer-likelihood-of-approval/ 2024-12-30T18:19:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amlenetug-h-lundbeck-parkinson-s-disease-likelihood-of-approval/ 2024-12-30T18:19:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lirilumab-bristol-myers-squibb-refractory-multiple-myeloma-likelihood-of-approval/ 2024-12-30T18:19:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amisulpride-acacia-pharma-chemotherapy-induced-nausea-and-vomiting-likelihood-of-approval/ 2024-12-30T18:19:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/utomilumab-pfizer-ovarian-cancer-likelihood-of-approval/ 2024-12-30T18:19:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilparencel-prokidney-type-2-diabetes-likelihood-of-approval/ 2024-12-30T18:18:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-biosimilar-r-pharm-breast-cancer-likelihood-of-approval/ 2024-12-30T18:18:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/metablok-arch-biopartners-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T18:18:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/poly-iclc-oncovir-solid-tumor-likelihood-of-approval/ 2024-12-30T18:18:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vas-01-vasgene-therapeutics-prostate-cancer-likelihood-of-approval/ 2024-12-30T18:18:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rocatinlimab-kyowa-kirin-prurigo-likelihood-of-approval/ 2024-12-30T18:18:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avelumab-merck-gastrointestinal-stromal-tumor-gist-likelihood-of-approval/ 2024-12-30T18:18:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blsh-01-moa-life-plus-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T18:18:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/com-701-compugen-solid-tumor-likelihood-of-approval/ 2024-12-30T18:18:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zamaporvint-redx-pharma-extrahepatic-bile-duct-cancer-likelihood-of-approval/ 2024-12-30T18:18:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asn-90-asceneuron-parkinson-s-disease-likelihood-of-approval/ 2024-12-30T18:18:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mesenchymal-stromal-cell-therapy-orbsen-therapeutics-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2024-12-30T18:18:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tinostamustine-northlake-international-multiple-myeloma-kahler-disease-likelihood-of-approval/ 2024-12-30T18:18:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-ovarian-cancer-likelihood-of-approval/ 2024-12-30T18:18:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stenoparib-allarity-therapeutics-colon-cancer-likelihood-of-approval/ 2024-12-30T18:17:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nt-219-purple-biotech-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2024-12-30T18:17:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emavusertib-hydrochloride-curis-myelodysplastic-syndrome-likelihood-of-approval/ 2024-12-30T18:17:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neo-2734-epigene-therapeutics-chronic-myelomonocytic-leukemia-cmml-likelihood-of-approval/ 2024-12-30T18:17:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rvu-120-ryvu-therapeutics-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T18:17:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s1p-205-s1-biopharma-erectile-dysfunction-likelihood-of-approval/ 2024-12-30T18:17:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/isunakinra-buzzard-pharmaceuticals-colorectal-cancer-likelihood-of-approval/ 2024-12-30T18:17:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cwp-291-jw-pharmaceutical-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T18:17:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exidavnemab-bioarctic-parkinson-s-disease-likelihood-of-approval/ 2024-12-30T18:17:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lgk-974-novartis-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2024-12-30T18:17:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fasudil-woolsey-pharmaceuticals-corticobasal-degeneration-cbd-cbgd-cortical-basal-ganglionic-degeneration-likelihood-of-approval/ 2024-12-30T18:17:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mp-1032-metriopharm-inflammatory-bowel-disease-likelihood-of-approval/ 2024-12-30T18:17:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lorecivivint-biosplice-therapeutics-osteoarthritis-likelihood-of-approval/ 2024-12-30T18:16:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hiv-vaccine-auro-vaccines-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2024-12-30T18:16:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/utidelone-biostar-pharmaceuticals-soft-tissue-sarcoma-likelihood-of-approval/ 2024-12-30T18:16:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navtemadlin-kartos-therapeutics-soft-tissue-sarcoma-likelihood-of-approval/ 2024-12-30T18:16:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inobrodib-cellcentric-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-30T18:16:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/quisovalimab-avalo-therapeutics-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2024-12-30T18:16:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iltamiocel-cook-myosite-dysphagia-likelihood-of-approval/ 2024-12-30T18:16:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/peginterferon-lambda-1a-eiger-biopharmaceuticals-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T18:14:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/utomilumab-pfizer-colorectal-cancer-likelihood-of-approval/ 2024-12-30T18:14:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-30T18:14:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mp-1032-metriopharm-multiple-sclerosis-likelihood-of-approval/ 2024-12-30T18:14:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/birtamimab-prothena-corp-primary-systemic-amyloidosis-likelihood-of-approval/ 2024-12-30T18:14:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paxalisib-kazia-therapeutics-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T18:14:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tinostamustine-mundipharma-edo-mantle-cell-lymphoma-likelihood-of-approval/ 2024-12-30T18:14:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navtemadlin-kartos-therapeutics-metastatic-melanoma-likelihood-of-approval/ 2024-12-30T18:13:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navtemadlin-kartos-therapeutics-multiple-myeloma-kahler-disease-likelihood-of-approval/ 2024-12-30T18:13:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/durvalumab-astrazeneca-germ-cell-tumors-likelihood-of-approval/ 2024-12-30T18:13:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nemolizumab-galderma-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2024-12-30T18:13:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/flucytosine-er-vocimagene-amiretrorepvec-denovo-biopharma-high-grade-glioma-likelihood-of-approval/ 2024-12-30T18:13:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ebselen-sound-pharmaceuticals-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T18:13:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lifileucel-iovance-biotherapeutics-primary-cns-lymphoma-likelihood-of-approval/ 2024-12-30T18:13:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lifileucel-iovance-biotherapeutics-rhabdomyosarcoma-likelihood-of-approval/ 2024-12-30T18:13:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-nasopharyngeal-cancer-likelihood-of-approval/ 2024-12-30T18:13:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-thymic-carcinoma-likelihood-of-approval/ 2024-12-30T18:13:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tevimbra-beigene-follicular-lymphoma-likelihood-of-approval/ 2024-12-30T18:13:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paxalisib-kazia-therapeutics-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T18:13:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/satralizumab-f-hoffmann-la-roche-duchenne-muscular-dystrophy-likelihood-of-approval/ 2024-12-30T18:12:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-penile-cancer-likelihood-of-approval/ 2024-12-30T18:12:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lixadesiran-pixofisiran-sirnaomics-keloids-likelihood-of-approval/ 2024-12-30T18:12:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lixadesiran-pixofisiran-sirnaomics-abdominal-obesity-likelihood-of-approval/ 2024-12-30T18:12:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/calquence-astrazeneca-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T18:12:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dostarlimab-gsk-duodenal-cancer-likelihood-of-approval/ 2024-12-30T18:12:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/suplatast-tosilate-melius-pharma-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2024-12-30T18:12:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gemcitabine-hydrochloride-innopharmax-lung-cancer-likelihood-of-approval/ 2024-12-30T18:12:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olx-07010-oligomerix-tauopathies-likelihood-of-approval/ 2024-12-30T18:12:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cm-24-purple-biotech-ovarian-cancer-likelihood-of-approval/ 2024-12-30T18:12:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lixadesiran-pixofisiran-sirnaomics-solid-tumor-likelihood-of-approval/ 2024-12-30T18:12:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/immune-globulin-human-grifols-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T18:12:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/p-128-gangagen-biotechnologies-staphylococcus-aureus-infections-likelihood-of-approval/ 2024-12-30T18:11:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bxq-350-bexion-pharmaceuticals-pediatric-diffuse-intrinsic-pontine-glioma-likelihood-of-approval/ 2024-12-30T18:11:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/influenza-strain-a-h5n1-vaccine-bluewillow-biologics-influenza-a-virus-h5n1-subtype-infections-likelihood-of-approval/ 2024-12-30T18:11:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/suplatast-tosilate-melius-pharma-cough-likelihood-of-approval/ 2024-12-30T18:11:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-321-biontech-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-12-30T18:11:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrilatazar-ability-pharmaceuticals-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T18:11:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-endometrial-cancer-likelihood-of-approval/ 2024-12-30T18:11:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/concizumab-novo-nordisk-hemophilia-b-factor-ix-deficiency-likelihood-of-approval/ 2024-12-30T18:11:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/calquence-astrazeneca-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T18:11:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-996-carmot-therapeutics-obesity-likelihood-of-approval/ 2024-12-30T18:11:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipl-344-immunity-pharma-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2024-12-30T18:11:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pritumumab-nascent-biotech-glioma-likelihood-of-approval/ 2024-12-30T18:10:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tolcapone-corino-therapeutics-familial-amyloid-cardiomyopathy-likelihood-of-approval/ 2024-12-30T18:10:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tolcapone-corino-therapeutics-amyloidosis-likelihood-of-approval/ 2024-12-30T18:10:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rvu-120-ryvu-therapeutics-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T18:10:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enfortumab-vedotin-astellas-pharma-solid-tumor-likelihood-of-approval/ 2024-12-30T18:10:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ketamine-seelos-therapeutics-complex-regional-pain-syndrome-sympathetic-reflex-dystrophy-reflex-sympathetic-dystrophy-likelihood-of-approval/ 2024-12-30T18:10:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ast-201-epithany-ovarian-cancer-likelihood-of-approval/ 2024-12-30T18:10:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-anaplastic-thyroid-cancer-likelihood-of-approval/ 2024-12-30T18:10:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lgk-974-novartis-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-30T18:10:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brilaroxazine-hydrochloride-reviva-pharmaceuticals-major-depressive-disorder-likelihood-of-approval/ 2024-12-30T18:10:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pamiparib-beigene-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T18:10:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pamiparib-beigene-peripheral-nerve-sheath-tumor-neurofibrosarcoma-likelihood-of-approval/ 2024-12-30T18:10:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2024-12-30T18:09:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eniluracil-processa-pharmaceuticals-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T18:09:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/debamestrocel-brainstorm-cell-therapeutics-alzheimer-s-disease-likelihood-of-approval/ 2024-12-30T18:09:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neucardin-zensun-shanghai-sci-tech-systolic-heart-failure-likelihood-of-approval/ 2024-12-30T18:09:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T18:09:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T18:09:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2024-12-30T18:09:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ebselen-sound-pharmaceuticals-meniere-disease-likelihood-of-approval/ 2024-12-30T18:09:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brevarex-mab-ar20-5-oncoquest-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T18:09:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dupilumab-regeneron-pharmaceuticals-dermatitis-eczema-likelihood-of-approval/ 2024-12-30T18:09:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stratagraft-mallinckrodt-burns-likelihood-of-approval/ 2024-12-30T18:09:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stenoparib-allarity-therapeutics-prostate-cancer-likelihood-of-approval/ 2024-12-30T18:09:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T18:08:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T18:08:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cannabidiol-jazz-pharmaceuticals-infantile-spasm-west-syndrome-likelihood-of-approval/ 2024-12-30T18:08:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/diacc-3010-evexta-bio-gastric-cancer-likelihood-of-approval/ 2024-12-30T18:08:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gammora-zion-medical-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T18:08:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tolinapant-taiho-pharmaceutical-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-30T18:08:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fasedienol-vistagen-therapeutics-social-anxiety-disorder-sad-social-phobia-likelihood-of-approval/ 2024-12-30T18:08:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fadraciclib-cyclacel-pharmaceuticals-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T18:08:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opaganib-redhill-biopharma-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2024-12-30T18:08:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dostarlimab-gsk-soft-tissue-sarcoma-likelihood-of-approval/ 2024-12-30T18:08:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irx-4204-io-therapeutics-parkinson-s-disease-likelihood-of-approval/ 2024-12-30T18:08:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sargramostim-partner-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T18:08:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prexasertib-mesylate-monohydrate-acrivon-therapeutics-refractory-medulloblastoma-likelihood-of-approval/ 2024-12-30T18:08:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-18038683-johnson-johnson-bipolar-disorder-manic-depression-likelihood-of-approval/ 2024-12-30T18:07:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zw-191-zymeworks-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-12-30T18:07:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zw-191-zymeworks-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T18:07:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-dae-hwa-pharmaceutical-angiosarcoma-likelihood-of-approval/ 2024-12-30T18:07:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lipocurc-signpath-pharma-metastatic-prostate-cancer-likelihood-of-approval/ 2024-12-30T18:07:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/solriamfetol-hydrochloride-axsome-therapeutics-shift-work-sleep-disorder-likelihood-of-approval/ 2024-12-30T18:07:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fostamatinib-disodium-rigel-pharmaceuticals-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T18:07:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-12-30T18:07:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/reparixin-dompe-farmaceutici-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2024-12-30T18:07:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aht-434-alterity-therapeutics-multiple-system-atrophy-msa-or-shy-drager-syndrome-or-multi-system-degeneration-likelihood-of-approval/ 2024-12-30T18:07:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/epacadostat-incyte-dedifferentiated-liposarcoma-likelihood-of-approval/ 2024-12-30T18:07:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efgartigimod-alfa-argenx-guillain-barre-syndrome-likelihood-of-approval/ 2024-12-30T18:07:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/insulin-human-aerami-therapeutics-type-2-diabetes-likelihood-of-approval/ 2024-12-30T18:07:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/insulin-human-aerami-therapeutics-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/ 2024-12-30T18:06:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selinexor-karyopharm-therapeutics-follicular-lymphoma-likelihood-of-approval/ 2024-12-30T18:06:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/deutetrabenazine-teva-pharmaceutical-industries-dystonia-likelihood-of-approval/ 2024-12-30T18:06:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/np-001-neuvivo-primary-progressive-multiple-sclerosis-ppms-likelihood-of-approval/ 2024-12-30T18:06:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incobotulinumtoxin-a-merz-therapeutics-unspecified-dermatological-disorders-likelihood-of-approval/ 2024-12-30T18:06:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dt-678-diapin-therapeutics-peripheral-arterial-disease-pad-peripheral-vascular-disease-pvd-likelihood-of-approval/ 2024-12-30T18:06:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dordaviprone-hydrochloride-chimerix-refractory-multiple-myeloma-likelihood-of-approval/ 2024-12-30T18:06:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dasatinib-bristol-myers-squibb-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T18:06:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/carfilzomib-amgen-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-12-30T18:06:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-metastatic-breast-cancer-likelihood-of-approval/ 2024-12-30T18:06:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rvu-120-ryvu-therapeutics-secondary-myelofibrosis-likelihood-of-approval/ 2024-12-30T18:06:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itacitinib-adipate-incyte-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-30T18:06:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tolinapant-taiho-pharmaceutical-anaplastic-large-cell-lymphoma-alcl-likelihood-of-approval/ 2024-12-30T18:05:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denileukin-diftitox-citius-oncology-endometrial-cancer-likelihood-of-approval/ 2024-12-30T18:05:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gvax-multiple-myeloma-vaccine-novartis-multiple-myeloma-kahler-disease-likelihood-of-approval/ 2024-12-30T18:05:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lgk-974-novartis-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2024-12-30T18:05:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imarikiren-scohia-pharma-diabetic-nephropathy-likelihood-of-approval/ 2024-12-30T18:05:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-papillary-renal-cell-carcinoma-likelihood-of-approval/ 2024-12-30T18:05:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stenoparib-allarity-therapeutics-metastatic-ovarian-cancer-likelihood-of-approval/ 2024-12-30T18:05:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cefiderocol-sulfate-tosylate-shionogi-sepsis-likelihood-of-approval/ 2024-12-30T18:05:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denileukin-diftitox-citius-oncology-melanoma-likelihood-of-approval/ 2024-12-30T18:05:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-f-hoffmann-la-roche-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-30T18:05:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-rhabdomyosarcoma-likelihood-of-approval/ 2024-12-30T18:05:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/relatlimab-bristol-myers-squibb-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T18:05:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/relatlimab-bristol-myers-squibb-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2024-12-30T18:05:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apalutamide-johnson-johnson-prostate-cancer-likelihood-of-approval/ 2024-12-30T18:04:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prexasertib-mesylate-monohydrate-acrivon-therapeutics-oral-cavity-mouth-cancer-likelihood-of-approval/ 2024-12-30T18:04:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-fallopian-tube-cancer-likelihood-of-approval/ 2024-12-30T18:04:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ir-vax-immunorestoration-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T18:04:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mp-1032-metriopharm-unspecified-infectious-diseases-likelihood-of-approval/ 2024-12-30T18:04:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zeripatamig-light-chain-bioscience-mantle-cell-lymphoma-likelihood-of-approval/ 2024-12-30T18:04:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/av-001-vasomune-therapeutics-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2024-12-30T18:04:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-30T18:04:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-neuroendocrine-carcinoma-likelihood-of-approval/ 2024-12-30T18:04:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T18:04:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/semorinemab-ac-immune-alzheimer-s-disease-likelihood-of-approval/ 2024-12-30T18:04:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nadunolimab-cantargia-squamous-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-30T18:04:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbp-501-canbas-breast-cancer-likelihood-of-approval/ 2024-12-30T18:03:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xevinapant-ascenta-therapeutics-gliosarcoma-likelihood-of-approval/ 2024-12-30T18:03:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pepinemab-vaccinex-alzheimer-s-disease-likelihood-of-approval/ 2024-12-30T18:03:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erdafitinib-johnson-johnson-lung-adenocarcinoma-likelihood-of-approval/ 2024-12-30T18:03:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/infliximab-biosimilar-celltrion-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T18:03:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hydromethylthionine-mesylate-taurx-pharmaceuticals-mild-cognitive-impairment-likelihood-of-approval/ 2024-12-30T18:03:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/survaxm-mimivax-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T18:03:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T18:03:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-nongerminomatous-nonseminomatous-germ-cell-tumors-likelihood-of-approval/ 2024-12-30T18:03:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-salivary-gland-cancer-likelihood-of-approval/ 2024-12-30T18:03:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-30T18:03:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asn-90-asceneuron-alzheimer-s-disease-likelihood-of-approval/ 2024-12-30T18:03:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mesenchymal-stromal-cell-therapy-orbsen-therapeutics-primary-sclerosing-cholangitis-likelihood-of-approval/ 2024-12-30T18:02:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ianalumab-novartis-systemic-sclerosis-scleroderma-likelihood-of-approval/ 2024-12-30T18:02:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erdafitinib-johnson-johnson-prostate-cancer-likelihood-of-approval/ 2024-12-30T18:02:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/surufatinib-hutchison-medipharma-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-12-30T18:02:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fadraciclib-cyclacel-pharmaceuticals-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2024-12-30T18:02:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lixadesiran-pixofisiran-sirnaomics-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-30T18:02:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/naquinate-haoma-medica-osteoporosis-likelihood-of-approval/ 2024-12-30T18:02:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vcn-01-theriva-biologics-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-12-30T18:02:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lirilumab-bristol-myers-squibb-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-12-30T18:02:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avelumab-merck-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-30T18:02:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inobrodib-cellcentric-refractory-multiple-myeloma-likelihood-of-approval/ 2024-12-30T18:02:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitazalimab-alligator-bioscience-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T18:02:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-colon-cancer-likelihood-of-approval/ 2024-12-30T18:02:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/birch-triterpenes-chiesi-farmaceutici-radiodermatitis-likelihood-of-approval-3/ 2024-12-30T18:01:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ozanimod-hydrochloride-bristol-myers-squibb-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T18:01:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xevinapant-ascenta-therapeutics-anaplastic-astrocytoma-likelihood-of-approval/ 2024-12-30T18:01:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mirdametinib-springworks-therapeutics-letterer-siwe-disease-multifocal-and-multisystemic-disseminated-langerhans-cell-histiocytosis-likelihood-of-approval/ 2024-12-30T18:01:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pridopidine-hydrochloride-prilenia-therapeutics-development-demyelinating-diseases-likelihood-of-approval/ 2024-12-30T18:01:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crizotinib-pfizer-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2024-12-30T18:01:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-oral-cavity-mouth-cancer-likelihood-of-approval/ 2024-12-30T18:01:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonidegib-phosphate-sun-pharma-advanced-research-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-30T18:01:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dupilumab-regeneron-pharmaceuticals-unspecified-respiratory-disorders-likelihood-of-approval/ 2024-12-30T18:01:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tolinapant-taiho-pharmaceutical-t-cell-lymphomas-likelihood-of-approval/ 2024-12-30T18:01:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nbm-bmx-naturewise-biotech-medicals-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T18:01:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nerofe-immune-system-key-alzheimer-s-disease-likelihood-of-approval/ 2024-12-30T18:01:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bxq-350-bexion-pharmaceuticals-malignant-glioma-likelihood-of-approval/ 2024-12-30T18:01:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anifrolumab-astrazeneca-dermatomyositis-likelihood-of-approval/ 2024-12-30T18:00:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avicursen-percheron-therapeutics-relapsing-remitting-multiple-sclerosis-rrms-likelihood-of-approval/ 2024-12-30T18:00:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lgk-974-novartis-lung-cancer-likelihood-of-approval/ 2024-12-30T18:00:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T18:00:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-esophageal-cancer-likelihood-of-approval/ 2024-12-30T18:00:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tolinapant-taiho-pharmaceutical-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T18:00:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/immune-globulin-human-csl-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-12-30T18:00:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bp-1002-bio-path-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-30T17:59:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adxsher-2-os-therapies-breast-cancer-likelihood-of-approval/ 2024-12-30T17:59:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivozanib-hydrochloride-aveo-pharmaceuticals-vulvar-cancer-likelihood-of-approval/ 2024-12-30T17:59:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-30T17:59:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imeglimin-poxel-type-2-diabetes-likelihood-of-approval/ 2024-12-30T17:59:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-813160-bristol-myers-squibb-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-12-30T17:59:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T17:59:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denileukin-diftitox-citius-oncology-mycosis-fungoides-likelihood-of-approval/ 2024-12-30T17:59:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denileukin-diftitox-citius-oncology-sezary-syndrome-likelihood-of-approval/ 2024-12-30T17:59:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apabetalone-resverlogix-post-acute-sequelae-of-covid-2019-pasc-or-long-covid-likelihood-of-approval/ 2024-12-30T17:59:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sovateltide-pharmazz-hypoxic-ischemic-encephalopathy-likelihood-of-approval/ 2024-12-30T17:59:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-metastatic-brain-tumor-likelihood-of-approval/ 2024-12-30T17:59:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sinecatechins-medigene-actinic-solar-keratosis-likelihood-of-approval/ 2024-12-30T17:59:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-metastatic-breast-cancer-likelihood-of-approval/ 2024-12-30T17:58:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fadraciclib-cyclacel-pharmaceuticals-uterine-cancer-likelihood-of-approval/ 2024-12-30T17:58:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/isunakinra-buzzard-pharmaceuticals-prostate-cancer-likelihood-of-approval/ 2024-12-30T17:58:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lifileucel-iovance-biotherapeutics-ewing-sarcoma-likelihood-of-approval/ 2024-12-30T17:58:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/terlipressin-ferring-international-center-unspecified-respiratory-disorders-likelihood-of-approval/ 2024-12-30T17:58:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitravatinib-malate-bristol-myers-squibb-well-differentiated-liposarcoma-likelihood-of-approval/ 2024-12-30T17:58:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitravatinib-malate-bristol-myers-squibb-soft-tissue-sarcoma-likelihood-of-approval/ 2024-12-30T17:58:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talazoparib-pfizer-breast-cancer-likelihood-of-approval/ 2024-12-30T17:58:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/defibrotide-sodium-jazz-pharmaceuticals-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2024-12-30T17:58:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zenuzolac-inovio-pharmaceuticals-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2024-12-30T17:58:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/capsaicin-grunenthal-chemotherapy-induced-peripheral-neuropathy-likelihood-of-approval/ 2024-12-30T17:58:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/picotamide-capithera-migraine-likelihood-of-approval/ 2024-12-30T17:58:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vcn-01-theriva-biologics-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2024-12-30T17:57:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/darolutamide-orion-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T17:57:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitravatinib-malate-bristol-myers-squibb-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2024-12-30T17:57:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azeliragon-cantex-pharmaceuticals-cognitive-impairment-likelihood-of-approval/ 2024-12-30T17:57:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lixadesiran-pixofisiran-sirnaomics-hypertrophic-scars-likelihood-of-approval/ 2024-12-30T17:57:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lixadesiran-pixofisiran-sirnaomics-basal-cell-carcinoma-basal-cell-epithelioma-likelihood-of-approval/ 2024-12-30T17:57:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/senaparib-impact-therapeutics-solid-tumor-likelihood-of-approval/ 2024-12-30T17:57:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctb-201-trove-therapeutics-sinusitis-likelihood-of-approval/ 2024-12-30T17:57:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/isunakinra-buzzard-pharmaceuticals-anal-cancer-likelihood-of-approval/ 2024-12-30T17:57:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crizotinib-pfizer-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-30T17:57:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pacibekitug-tourmaline-bio-graves-ophthalmopathy-likelihood-of-approval/ 2024-12-30T17:57:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brilaroxazine-hydrochloride-reviva-pharmaceuticals-schizophrenia-likelihood-of-approval/ 2024-12-30T17:57:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/encequidar-mesylate-paclitaxel-hanmi-pharmaceuticals-breast-cancer-likelihood-of-approval/ 2024-12-30T17:57:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sargramostim-partner-therapeutics-metastatic-melanoma-likelihood-of-approval/ 2024-12-30T17:56:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sargramostim-partner-therapeutics-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T17:56:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/seviteronel-innocrin-pharmaceuticals-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-30T17:56:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-oropharyngeal-cancer-likelihood-of-approval/ 2024-12-30T17:56:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exebacase-aurobac-therapeutics-prosthetic-joint-infections-likelihood-of-approval/ 2024-12-30T17:56:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-588-biotest-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T17:56:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ribociclib-succinate-novartis-anaplastic-astrocytoma-likelihood-of-approval/ 2024-12-30T17:56:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eniluracil-processa-pharmaceuticals-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-30T17:56:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sargramostim-partner-therapeutics-hematological-tumor-likelihood-of-approval/ 2024-12-30T17:56:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tipapkinogene-sovacivec-transgene-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-30T17:56:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-836826-boehringer-ingelheim-international-unspecified-respiratory-disorders-likelihood-of-approval/ 2024-12-30T17:56:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-neuroendocrine-tumors-likelihood-of-approval/ 2024-12-30T17:56:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-metastatic-brain-tumor-likelihood-of-approval/ 2024-12-30T17:56:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/belapectin-galectin-therapeutics-portal-hypertension-likelihood-of-approval/ 2024-12-30T17:55:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lgk-974-novartis-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T17:55:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denileukin-diftitox-citius-oncology-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T17:55:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denileukin-diftitox-citius-oncology-solid-tumor-likelihood-of-approval/ 2024-12-30T17:55:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lutetium-lu-177-dotatate-advanced-accelerator-applications-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T17:55:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/survaxm-mimivax-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T17:55:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trametinib-dimethyl-sulfoxide-uprosertib-novartis-endometrial-cancer-likelihood-of-approval/ 2024-12-30T17:55:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/interferon-gamma-1b-amgen-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T17:55:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nelfinavir-mesylate-pfizer-refractory-multiple-myeloma-likelihood-of-approval/ 2024-12-30T17:55:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prexasertib-mesylate-monohydrate-acrivon-therapeutics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-30T17:55:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vandefitemcel-sanbio-traumatic-brain-injury-likelihood-of-approval/ 2024-12-30T17:55:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adakitug-bristol-myers-squibb-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T17:55:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ebselen-sound-pharmaceuticals-drug-toxicity-likelihood-of-approval/ 2024-12-30T17:55:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eom-613-eom-pharmaceuticals-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2024-12-30T17:54:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xanomeline-bristol-myers-squibb-alzheimer-s-disease-likelihood-of-approval/ 2024-12-30T17:54:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eom-613-eom-pharmaceuticals-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2024-12-30T17:54:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fadraciclib-cyclacel-pharmaceuticals-unspecified-b-cell-lymphomas-likelihood-of-approval/ 2024-12-30T17:54:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eniluracil-processa-pharmaceuticals-metastatic-breast-cancer-likelihood-of-approval/ 2024-12-30T17:54:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/immune-globulin-human-csl-post-acute-sequelae-of-covid-2019-pasc-or-long-covid-likelihood-of-approval/ 2024-12-30T17:54:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nelfinavir-mesylate-pfizer-relapsed-multiple-myeloma-likelihood-of-approval-2/ 2024-12-30T17:54:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pitolisant-hydrochloride-bioprojet-scr-autism-spectrum-disorder-asd-likelihood-of-approval/ 2024-12-30T17:54:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tipapkinogene-sovacivec-transgene-oropharyngeal-cancer-likelihood-of-approval/ 2024-12-30T17:54:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/margetuximab-macrogenics-cervical-cancer-likelihood-of-approval/ 2024-12-30T17:54:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/astodrimer-starpharma-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T17:54:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/np-001-neuvivo-huntington-disease-likelihood-of-approval/ 2024-12-30T17:54:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rusalatide-acetate-chrysalis-biotherapeutics-radiation-toxicity-radiation-sickness-acute-radiation-syndrome-likelihood-of-approval/ 2024-12-30T17:54:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibudilast-medicinova-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2024-12-30T17:53:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/interferon-gamma-1b-amgen-myelodysplastic-syndrome-likelihood-of-approval/ 2024-12-30T17:53:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elamipretide-hydrochloride-stealth-biotherapeutics-mitochondrial-myopathy-likelihood-of-approval/ 2024-12-30T17:53:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/concizumab-novo-nordisk-hemophilia-a-factor-viii-deficiency-likelihood-of-approval/ 2024-12-30T17:53:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tolinapant-taiho-pharmaceutical-t-cell-leukemia-likelihood-of-approval/ 2024-12-30T17:53:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mocravimod-hydrochloride-priothera-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-12-30T17:53:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/felzartamab-biogen-lupus-nephritis-likelihood-of-approval/ 2024-12-30T17:53:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/n-115-emphycorp-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T17:53:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tolinapant-taiho-pharmaceutical-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T17:53:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tolinapant-taiho-pharmaceutical-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-30T17:53:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prexasertib-mesylate-monohydrate-acrivon-therapeutics-hypopharyngeal-cancer-likelihood-of-approval/ 2024-12-30T17:53:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fostamatinib-disodium-rigel-pharmaceuticals-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2024-12-30T17:53:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abemaciclib-eli-lilly-and-co-neuroendocrine-gastroenteropancreatic-tumors-gep-net-likelihood-of-approval/ 2024-12-30T17:52:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval/ 2024-12-30T17:52:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-neuroendocrine-tumors-likelihood-of-approval/ 2024-12-30T17:52:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/valiltramiprosate-alzheon-unspecified-central-nervous-system-disorders-likelihood-of-approval/ 2024-12-30T17:52:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/clazakizumab-csl-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T17:52:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/otilimab-gsk-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2024-12-30T17:52:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cobimetinib-fumarate-f-hoffmann-la-roche-soft-tissue-sarcoma-likelihood-of-approval/ 2024-12-30T17:52:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/delamanid-otsuka-pharmaceutical-pulmonary-tuberculosis-likelihood-of-approval/ 2024-12-30T17:52:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-squamous-cell-carcinoma-likelihood-of-approval/ 2024-12-30T17:52:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incobotulinumtoxin-a-merz-therapeutics-unspecified-musculoskeletal-disorders-likelihood-of-approval/ 2024-12-30T17:52:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval/ 2024-12-30T17:52:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mirvetuximab-soravtansine-abbvie-endometrial-cancer-likelihood-of-approval/ 2024-12-30T17:52:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talfirastide-constant-therapeutics-ischemic-stroke-likelihood-of-approval/ 2024-12-30T17:52:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plinabulin-beyondspring-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T17:51:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-30T17:51:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/everolimus-novartis-high-grade-glioma-likelihood-of-approval/ 2024-12-30T17:51:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ingenol-mebutate-leo-pharma-basal-cell-carcinoma-basal-cell-epithelioma-likelihood-of-approval/ 2024-12-30T17:51:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-pediatric-diffuse-intrinsic-pontine-glioma-likelihood-of-approval/ 2024-12-30T17:51:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T17:51:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bp-1002-bio-path-cutaneous-t-cell-lymphoma-likelihood-of-approval/ 2024-12-30T17:51:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rtn-001-retension-pharmaceuticals-hypertension-likelihood-of-approval/ 2024-12-30T17:51:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/g-207-treovir-high-grade-glioma-likelihood-of-approval/ 2024-12-30T17:51:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-12-30T17:51:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T17:51:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/np-001-neuvivo-muscular-dystrophy-likelihood-of-approval/ 2024-12-30T17:51:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alecsat-cytovac-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T17:51:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-medulloblastoma-likelihood-of-approval/ 2024-12-30T17:50:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T17:50:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/padeliporfin-potassium-impact-biotech-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T17:50:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tolinapant-taiho-pharmaceutical-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T17:50:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tolinapant-taiho-pharmaceutical-head-and-neck-cancer-likelihood-of-approval/ 2024-12-30T17:50:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alisporivir-debiopharm-international-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T17:50:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/genistein-humanetics-post-acute-sequelae-of-covid-2019-pasc-or-long-covid-likelihood-of-approval/ 2024-12-30T17:50:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xentuzumab-boehringer-ingelheim-international-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-30T17:50:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/temelimab-geneuro-unspecified-central-nervous-system-disorders-likelihood-of-approval/ 2024-12-30T17:50:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitravatinib-malate-bristol-myers-squibb-liposarcoma-likelihood-of-approval/ 2024-12-30T17:50:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitravatinib-malate-bristol-myers-squibb-rhabdomyosarcoma-likelihood-of-approval/ 2024-12-30T17:50:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pomalidomide-bristol-myers-squibb-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-12-30T17:50:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-thymocyte-globulin-rabbit-neovii-pharmaceuticals-myelodysplastic-syndrome-likelihood-of-approval/ 2024-12-30T17:49:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ribociclib-succinate-novartis-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T17:49:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prexasertib-mesylate-monohydrate-acrivon-therapeutics-laryngeal-cancer-likelihood-of-approval/ 2024-12-30T17:49:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/veliparib-er-abbvie-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-12-30T17:49:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/relenopride-sk-life-science-unspecified-neurologic-disorders-likelihood-of-approval/ 2024-12-30T17:49:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denileukin-diftitox-citius-oncology-renal-cell-carcinoma-likelihood-of-approval/ 2024-12-30T17:49:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prexasertib-mesylate-monohydrate-acrivon-therapeutics-oropharyngeal-cancer-likelihood-of-approval/ 2024-12-30T17:49:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-thymocyte-globulin-rabbit-neovii-pharmaceuticals-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-12-30T17:49:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/defactinib-hydrochloride-verastem-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T17:49:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/estetrol-gedeon-richter-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T17:49:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emapalumab-swedish-orphan-biovitrum-cytopenia-likelihood-of-approval/ 2024-12-30T17:49:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-30T17:49:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-peritoneal-cancer-likelihood-of-approval/ 2024-12-30T17:49:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-fallopian-tube-cancer-likelihood-of-approval/ 2024-12-30T17:48:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-osteosarcoma-likelihood-of-approval/ 2024-12-30T17:48:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lam-181-laminar-pharmaceuticals-neuropathic-pain-neuralgia-likelihood-of-approval/ 2024-12-30T17:48:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T17:48:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-chordoma-likelihood-of-approval/ 2024-12-30T17:48:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atrasentan-hydrochloride-novartis-focal-segmental-glomerulosclerosis-fsgs-likelihood-of-approval/ 2024-12-30T17:48:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prexasertib-mesylate-monohydrate-acrivon-therapeutics-recurrent-medulloblastoma-likelihood-of-approval/ 2024-12-30T17:48:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patiromer-sorbitex-calcium-vifor-pharma-management-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2024-12-30T17:48:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/np-001-neuvivo-frontotemporal-dementia-ftd-likelihood-of-approval/ 2024-12-30T17:48:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/treprostinil-united-therapeutics-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2024-12-30T17:48:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atibuclimab-implicit-bioscience-parkinson-s-disease-likelihood-of-approval/ 2024-12-30T17:48:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bavituximab-feng-biosciences-gliosarcoma-likelihood-of-approval/ 2024-12-30T17:48:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-peritoneal-cancer-likelihood-of-approval/ 2024-12-30T17:48:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-ewing-sarcoma-likelihood-of-approval/ 2024-12-30T17:47:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-neuroblastoma-likelihood-of-approval/ 2024-12-30T17:47:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lactin-v-osel-unspecified-gynecological-disorders-likelihood-of-approval/ 2024-12-30T17:47:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibcasertib-shenzhen-chipscreen-biosciences-colon-cancer-likelihood-of-approval/ 2024-12-30T17:47:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nerinetide-nono-acute-ischemic-stroke-likelihood-of-approval/ 2024-12-30T17:47:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anamorelin-hydrochloride-helsinn-healthcare-obesity-likelihood-of-approval/ 2024-12-30T17:47:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ms-20-microbio-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T17:47:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-endometrial-cancer-likelihood-of-approval/ 2024-12-30T17:47:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pt-150-palisades-therapeutics-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T17:47:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apn-01-apeiron-biologics-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T17:47:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anifrolumab-astrazeneca-chronic-cutaneous-lupus-erythematosus-ccle-discoid-lupus-erythematosus-dle-likelihood-of-approval/ 2024-12-30T17:47:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T17:47:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-30T17:47:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibcasertib-shenzhen-chipscreen-biosciences-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-30T17:46:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ose-2101-ose-immunotherapeutics-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T17:46:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T17:46:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omacetaxine-mepesuccinate-teva-pharmaceutical-industries-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T17:46:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rintatolimod-aim-immunotech-peritoneal-cancer-likelihood-of-approval/ 2024-12-30T17:46:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lurbinectedin-pharma-mar-sarcomas-likelihood-of-approval/ 2024-12-30T17:46:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/veliparib-er-abbvie-chronic-myelocytic-leukemia-cml-chronic-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T17:46:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-cervical-cancer-likelihood-of-approval/ 2024-12-30T17:46:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anifrolumab-astrazeneca-polymyositis-likelihood-of-approval/ 2024-12-30T17:46:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arbaclofen-allos-pharma-unspecified-genetic-disorders-likelihood-of-approval/ 2024-12-30T17:46:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obexelimab-zenas-biopharma-usa-multiple-sclerosis-likelihood-of-approval/ 2024-12-30T17:46:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atrasentan-hydrochloride-novartis-kidney-disease-nephropathy-likelihood-of-approval/ 2024-12-30T17:46:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axelopran-theravance-biopharma-opioid-induced-constipation-oic-likelihood-of-approval/ 2024-12-30T17:46:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crizanlizumab-novartis-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T17:46:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T17:45:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aglatimagene-besadenovec-candel-therapeutics-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T17:45:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mvi-816-madison-vaccines-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-30T17:45:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cenobamate-sk-life-science-liver-failure-hepatic-insufficiency-likelihood-of-approval/ 2024-12-30T17:45:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pt-150-palisades-therapeutics-alcohol-dependence-likelihood-of-approval/ 2024-12-30T17:45:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bertilimumab-satellos-bioscience-vernal-keratoconjunctivitis-likelihood-of-approval/ 2024-12-30T17:45:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tafasitamab-incyte-follicular-lymphoma-likelihood-of-approval/ 2024-12-30T17:45:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tapinarof-dermavant-sciences-palmoplantar-keratoderma-likelihood-of-approval/ 2024-12-30T17:45:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asunercept-apogenix-unspecified-dermatological-disorders-likelihood-of-approval/ 2024-12-30T17:45:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xevinapant-ascenta-therapeutics-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T17:45:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/veliparib-er-abbvie-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T17:45:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evenamide-newron-pharmaceuticals-schizophrenia-likelihood-of-approval/ 2024-12-30T17:45:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tafasitamab-incyte-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T17:45:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xevinapant-ascenta-therapeutics-high-grade-glioma-likelihood-of-approval/ 2024-12-30T17:44:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/veliparib-er-abbvie-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T17:44:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-ovarian-cancer-likelihood-of-approval/ 2024-12-30T17:44:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atrasentan-hydrochloride-novartis-iga-nephropathy-berger-s-disease-likelihood-of-approval/ 2024-12-30T17:44:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atrasentan-hydrochloride-novartis-diabetic-nephropathy-likelihood-of-approval/ 2024-12-30T17:44:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pt-150-palisades-therapeutics-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T17:44:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/budoprutug-climb-bio-membranous-glomerulonephritis-likelihood-of-approval/ 2024-12-30T17:44:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/narsoplimab-omeros-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T17:44:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/veliparib-er-abbvie-myelofibrosis-likelihood-of-approval/ 2024-12-30T17:44:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azeliragon-cantex-pharmaceuticals-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T17:44:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evt-401-evotec-rheumatoid-arthritis-likelihood-of-approval/ 2024-12-30T17:44:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dovramilast-medicines-development-for-global-health-tuberculosis-likelihood-of-approval/ 2024-12-30T17:44:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/guadecitabine-sodium-astex-pharmaceuticals-t-cell-lymphomas-likelihood-of-approval/ 2024-12-30T17:44:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afamelanotide-acetate-clinuvel-pharmaceuticals-unspecified-dermatological-disorders-likelihood-of-approval/ 2024-12-30T17:43:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bio-11006-biomarck-pharmaceuticals-osteosarcoma-likelihood-of-approval/ 2024-12-30T17:43:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nitazoxanide-cr-romark-laboratories-lc-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T17:43:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tafasitamab-incyte-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval/ 2024-12-30T17:43:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/liraglutide-novo-nordisk-obesity-likelihood-of-approval/ 2024-12-30T17:43:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zabadinostat-ingenox-therapeutics-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-30T17:43:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tafasitamab-incyte-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T17:43:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/belimumab-gsk-interstitial-lung-diseases-diffuse-parenchymal-lung-disease-likelihood-of-approval/ 2024-12-30T17:43:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ir-vax-immunorestoration-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-30T17:43:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ir-vax-immunorestoration-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-30T17:43:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bit-225-biotron-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2024-12-30T17:43:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/n-115-emphycorp-post-acute-sequelae-of-covid-2019-pasc-or-long-covid-likelihood-of-approval/ 2024-12-30T17:43:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-101-a28-therapeutics-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-30T17:43:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bp-1002-bio-path-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2024-12-30T17:43:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/saroglitazar-zydus-therapeutics-polycystic-ovarian-syndrome-likelihood-of-approval/ 2024-12-30T17:42:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trabedersen-sapu-bioscience-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T17:42:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/donaperminogene-seltoplasmid-helixmith-intermittent-claudication-likelihood-of-approval/ 2024-12-30T17:42:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obeticholic-acid-intercept-pharmaceuticals-biliary-atresia-likelihood-of-approval/ 2024-12-30T17:42:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aad-2004-gnt-pharma-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2024-12-30T17:42:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vb-201-notable-labs-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T17:42:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onabotulinumtoxin-a-abbvie-unspecified-musculoskeletal-disorders-likelihood-of-approval/ 2024-12-30T17:42:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/veliparib-er-abbvie-myeloproliferative-disorders-likelihood-of-approval/ 2024-12-30T17:42:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ripasudil-hydrochloride-hydrate-kowa-retinopathy-of-prematurity-likelihood-of-approval/ 2024-12-30T17:42:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/catequentinib-hydrochloride-advenchen-laboratories-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T17:42:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apatinib-mesylate-elevar-therapeutics-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-30T17:42:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/topiramate-curx-pharmaceuticals-migraine-likelihood-of-approval/ 2024-12-30T17:42:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/liraglutide-novo-nordisk-alzheimer-s-disease-likelihood-of-approval/ 2024-12-30T17:42:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tempol-matrix-biomed-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T17:41:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pt-150-palisades-therapeutics-prostate-cancer-likelihood-of-approval/ 2024-12-30T17:41:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pt-150-palisades-therapeutics-ovarian-cancer-likelihood-of-approval/ 2024-12-30T17:41:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivozanib-hydrochloride-aveo-pharmaceuticals-breast-cancer-likelihood-of-approval/ 2024-12-30T17:41:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dexpramipexole-dihydrochloride-areteia-therapeutics-chronic-obstructive-pulmonary-disease-copd-likelihood-of-approval/ 2024-12-30T17:41:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zenuzolac-inovio-pharmaceuticals-diabetic-nephropathy-likelihood-of-approval/ 2024-12-30T17:41:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omacetaxine-mepesuccinate-teva-pharmaceutical-industries-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T17:41:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eculizumab-alexion-pharmaceuticals-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2024-12-30T17:41:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/censavudine-transposon-therapeutics-aicardi-goutieres-syndrome-ags-likelihood-of-approval/ 2024-12-30T17:41:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/veligrotug-viridian-therapeutics-graves-ophthalmopathy-likelihood-of-approval/ 2024-12-30T17:41:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zinpentraxin-alfa-f-hoffmann-la-roche-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2024-12-30T17:41:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lg-631-lentigen-technology-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T17:41:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegfilgrastim-pharmaessentia-neutropenia-likelihood-of-approval/ 2024-12-30T17:41:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbl-0137-incuron-lymphoma-likelihood-of-approval/ 2024-12-30T17:40:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rintatolimod-aim-immunotech-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T17:40:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bavituximab-feng-biosciences-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T17:40:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ensifentrine-verona-pharma-bronchiectasis-likelihood-of-approval/ 2024-12-30T17:40:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mydicar-sardocor-systolic-heart-failure-likelihood-of-approval/ 2024-12-30T17:40:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rifaximin-alfasigma-sickle-cell-disease-likelihood-of-approval/ 2024-12-30T17:40:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vemurafenib-f-hoffmann-la-roche-bladder-cancer-likelihood-of-approval/ 2024-12-30T17:40:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/defibrotide-sodium-jazz-pharmaceuticals-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2024-12-30T17:40:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zenuzolac-inovio-pharmaceuticals-inflammation-likelihood-of-approval/ 2024-12-30T17:40:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-solid-tumor-likelihood-of-approval/ 2024-12-30T17:40:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omadacycline-tosylate-paratek-pharmaceuticals-osteomyelitis-likelihood-of-approval/ 2024-12-30T17:40:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azacitidine-bristol-myers-squibb-polycythemia-vera-likelihood-of-approval/ 2024-12-30T17:40:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tasquinimod-active-biotech-post-polycythemia-vera-myelofibrosis-ppv-mf-likelihood-of-approval/ 2024-12-30T17:40:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tasquinimod-active-biotech-chronic-idiopathic-myelofibrosis-primary-myelofibrosis-likelihood-of-approval/ 2024-12-30T17:40:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tagraxofusp-stemline-therapeutics-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T17:39:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibudilast-medicinova-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2024-12-30T17:39:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbl-0137-incuron-central-nervous-system-cns-tumor-likelihood-of-approval/ 2024-12-30T17:39:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pexastimogene-devacirepvec-sillajen-biotherapeutics-renal-cell-carcinoma-likelihood-of-approval/ 2024-12-30T17:39:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaparib-astrazeneca-cervical-cancer-likelihood-of-approval/ 2024-12-30T17:39:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ruxolitinib-phosphate-incyte-coronavirus-disease-2019-covid-19-associated-cytokine-release-syndrome-likelihood-of-approval/ 2024-12-30T17:39:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/polb-001-poolbeg-pharma-unspecified-influenza-virus-infections-likelihood-of-approval/ 2024-12-30T17:39:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/foralumab-tiziana-life-sciences-secondary-progressive-multiple-sclerosis-spms-likelihood-of-approval/ 2024-12-30T17:39:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mavoglurant-stalicla-alcohol-dependence-likelihood-of-approval/ 2024-12-30T17:39:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-merkel-cell-carcinoma-likelihood-of-approval/ 2024-12-30T17:39:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vemurafenib-f-hoffmann-la-roche-lung-adenocarcinoma-likelihood-of-approval/ 2024-12-30T17:39:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gedatolisib-celcuity-endometrial-cancer-likelihood-of-approval/ 2024-12-30T17:39:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gedatolisib-celcuity-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T17:39:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erdafitinib-johnson-johnson-muscle-invasive-bladder-cancer-mibc-likelihood-of-approval/ 2024-12-30T17:38:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itolizumab-equillium-graft-versus-host-disease-gvhd-likelihood-of-approval/ 2024-12-30T17:38:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vemurafenib-f-hoffmann-la-roche-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T17:38:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nanodox-ology-bioservices-wounds-likelihood-of-approval/ 2024-12-30T17:38:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tucatinib-pfizer-endometrial-cancer-likelihood-of-approval/ 2024-12-30T17:38:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eculizumab-alexion-pharmaceuticals-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2024-12-30T17:38:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eculizumab-alexion-pharmaceuticals-coronavirus-disease-2019-covid-19-associated-acute-lung-injury-likelihood-of-approval/ 2024-12-30T17:38:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/voclosporin-aurinia-pharmaceuticals-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T17:38:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/secukinumab-novartis-unspecified-dermatological-disorders-likelihood-of-approval/ 2024-12-30T17:38:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tremelimumab-astrazeneca-salivary-gland-cancer-likelihood-of-approval/ 2024-12-30T17:38:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/devimistat-cornerstone-pharmaceuticals-unspecified-b-cell-lymphomas-likelihood-of-approval/ 2024-12-30T17:38:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abgn-168h-altrubio-graft-versus-host-disease-gvhd-likelihood-of-approval/ 2024-12-30T17:38:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-soft-tissue-sarcoma-likelihood-of-approval/ 2024-12-30T17:38:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emapalumab-swedish-orphan-biovitrum-systemic-onset-juvenile-idiopathic-arthritis-still-disease-likelihood-of-approval/ 2024-12-30T17:38:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trametinib-dimethyl-sulfoxide-novartis-letterer-siwe-disease-multifocal-and-multisystemic-disseminated-langerhans-cell-histiocytosis-likelihood-of-approval/ 2024-12-30T17:37:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onalespib-astex-pharmaceuticals-mantle-cell-lymphoma-likelihood-of-approval/ 2024-12-30T17:37:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/entresto-novartis-left-ventricular-hypertrophy-likelihood-of-approval/ 2024-12-30T17:37:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aminolevulinic-acid-hydrochloride-biofrontera-cutaneous-squamous-cell-carcinoma-cscc-likelihood-of-approval/ 2024-12-30T17:37:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crizotinib-pfizer-metastatic-uveal-melanoma-likelihood-of-approval/ 2024-12-30T17:37:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apatinib-mesylate-elevar-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T17:37:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/topiramate-curx-pharmaceuticals-epilepsy-likelihood-of-approval/ 2024-12-30T17:37:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/secukinumab-novartis-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2024-12-30T17:37:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tremelimumab-astrazeneca-germ-cell-tumors-likelihood-of-approval/ 2024-12-30T17:37:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imetelstat-sodium-geron-juvenile-myelomonocytic-leukemia-jmml-likelihood-of-approval/ 2024-12-30T17:37:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gedatolisib-celcuity-cervical-cancer-likelihood-of-approval/ 2024-12-30T17:37:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adavosertib-astrazeneca-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T17:37:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/promacta-novartis-radiation-toxicity-radiation-sickness-acute-radiation-syndrome-likelihood-of-approval/ 2024-12-30T17:36:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/entolimod-statera-biopharma-radiation-toxicity-radiation-sickness-acute-radiation-syndrome-likelihood-of-approval/ 2024-12-30T17:36:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enzalutamide-pfizer-brenner-tumor-likelihood-of-approval/ 2024-12-30T17:36:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tremelimumab-astrazeneca-anal-cancer-likelihood-of-approval/ 2024-12-30T17:36:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/carperitide-daiichi-sankyo-contrast-induced-nephropathy-likelihood-of-approval/ 2024-12-30T17:36:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/murepavadin-spexis-bronchiectasis-likelihood-of-approval/ 2024-12-30T17:36:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fosravuconazole-eisai-fungal-infections-likelihood-of-approval/ 2024-12-30T17:36:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trametinib-dimethyl-sulfoxide-novartis-neurofibromatoses-type-i-von-recklinghausen-s-disease-likelihood-of-approval/ 2024-12-30T17:36:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azacitidine-bristol-myers-squibb-chronic-idiopathic-myelofibrosis-primary-myelofibrosis-likelihood-of-approval/ 2024-12-30T17:36:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tagraxofusp-stemline-therapeutics-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T17:36:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rintatolimod-aim-immunotech-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-12-30T17:36:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/isatuximab-sanofi-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T17:36:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pacibekitug-tourmaline-bio-atherosclerosis-likelihood-of-approval/ 2024-12-30T17:35:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ralinepag-xr-united-therapeutics-pulmonary-arterial-hypertension-likelihood-of-approval/ 2024-12-30T17:35:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brentuximab-vedotin-pfizer-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T17:35:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-cutaneous-squamous-cell-carcinoma-cscc-likelihood-of-approval/ 2024-12-30T17:35:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/budesonide-formoterol-fumarate-astrazeneca-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T17:35:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ponatinib-hydrochloride-takeda-pharmaceutical-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T17:34:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crofelemer-dr-napo-pharmaceuticals-chemotherapy-induced-diarrhea-cid-likelihood-of-approval/ 2024-12-30T17:34:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itolizumab-biocon-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2024-12-30T17:33:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/remestemcel-l-mesoblast-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2024-12-30T17:27:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/belimumab-gsk-rheumatoid-arthritis-likelihood-of-approval/ 2024-12-30T17:27:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fruquintinib-takeda-pharmaceutical-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T17:27:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pacibekitug-tourmaline-bio-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2024-12-30T17:27:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/baricitinib-eli-lilly-and-co-graft-versus-host-disease-gvhd-likelihood-of-approval/ 2024-12-30T17:27:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dalcetrapib-dalcor-pharmaceuticals-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T17:26:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/guadecitabine-sodium-astex-pharmaceuticals-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-30T17:26:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ozempic-novo-nordisk-peripheral-arterial-disease-pad-peripheral-vascular-disease-pvd-likelihood-of-approval/ 2024-12-30T17:26:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apremilast-amgen-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-12-30T17:26:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avn-322-avineuro-pharmaceuticals-cognitive-disorders-likelihood-of-approval/ 2024-12-30T17:26:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/remestemcel-l-mesoblast-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2024-12-30T17:26:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gedatolisib-celcuity-ovarian-cancer-likelihood-of-approval/ 2024-12-30T17:26:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fibromun-philogen-metastatic-melanoma-likelihood-of-approval/ 2024-12-30T17:26:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaparib-astrazeneca-endometrial-cancer-likelihood-of-approval/ 2024-12-30T17:26:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brentuximab-vedotin-pfizer-t-cell-lymphomas-likelihood-of-approval/ 2024-12-30T17:26:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ponatinib-hydrochloride-takeda-pharmaceutical-biliary-tumor-likelihood-of-approval/ 2024-12-30T17:26:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ponatinib-hydrochloride-takeda-pharmaceutical-central-nervous-system-cns-tumor-likelihood-of-approval/ 2024-12-30T17:26:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regorafenib-bayer-gliosarcoma-likelihood-of-approval/ 2024-12-30T17:26:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaparib-astrazeneca-malignant-mesothelioma-likelihood-of-approval/ 2024-12-30T17:25:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ponatinib-hydrochloride-takeda-pharmaceutical-lymphoma-likelihood-of-approval/ 2024-12-30T17:25:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/guadecitabine-sodium-astex-pharmaceuticals-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2024-12-30T17:25:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/entinostat-taizhou-yiteng-jingang-pharmaceutical-t-cell-lymphomas-likelihood-of-approval/ 2024-12-30T17:25:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/entinostat-taizhou-yiteng-jingang-pharmaceutical-unspecified-b-cell-lymphomas-likelihood-of-approval/ 2024-12-30T17:25:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brentuximab-vedotin-pfizer-angioimmunoblastic-t-cell-lymphoma-aitl-immunoblastic-lymphadenopathy-likelihood-of-approval/ 2024-12-30T17:25:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/guadecitabine-sodium-astex-pharmaceuticals-angioimmunoblastic-t-cell-lymphoma-aitl-immunoblastic-lymphadenopathy-likelihood-of-approval/ 2024-12-30T17:25:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neratinib-puma-biotechnology-ocular-melanoma-likelihood-of-approval/ 2024-12-30T17:25:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/collagenase-clostridium-histolyticum-endo-international-unspecified-musculoskeletal-disorders-likelihood-of-approval/ 2024-12-30T17:25:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azacitidine-bristol-myers-squibb-essential-thrombocythemia-likelihood-of-approval/ 2024-12-30T17:25:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anumigilimab-csl-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2024-12-30T17:25:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bosulif-pfizer-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-12-30T17:25:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/guadecitabine-sodium-astex-pharmaceuticals-cutaneous-t-cell-lymphoma-likelihood-of-approval/ 2024-12-30T17:25:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selumetinib-sulfate-astrazeneca-glioma-likelihood-of-approval-2/ 2024-12-30T17:24:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adavosertib-astrazeneca-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T17:24:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adavosertib-astrazeneca-endometrial-cancer-likelihood-of-approval/ 2024-12-30T17:24:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enobosarm-veru-muscle-wasting-disorders-likelihood-of-approval/ 2024-12-30T17:24:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cetuximab-eli-lilly-and-co-anal-cancer-likelihood-of-approval/ 2024-12-30T17:24:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/guadecitabine-sodium-astex-pharmaceuticals-anaplastic-large-cell-lymphoma-alcl-likelihood-of-approval/ 2024-12-30T17:24:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gedatolisib-celcuity-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-30T17:24:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volasertib-notable-labs-solid-tumor-likelihood-of-approval/ 2024-12-30T17:24:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ataluren-ptc-therapeutics-duchenne-muscular-dystrophy-likelihood-of-approval/ 2024-12-30T17:24:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/buntanetap-tartrate-annovis-bio-frontotemporal-dementia-ftd-likelihood-of-approval/ 2024-12-30T17:24:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neratinib-puma-biotechnology-colon-cancer-likelihood-of-approval/ 2024-12-30T17:24:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/moxidectin-medicines-development-for-global-health-elephantiasis-lymphatic-filariasis-likelihood-of-approval/ 2024-12-30T17:24:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tasquinimod-active-biotech-post-essential-thrombocythemia-myelofibrosis-post-et-mf-likelihood-of-approval/ 2024-12-30T17:24:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dalbavancin-abbvie-mycoses-likelihood-of-approval/ 2024-12-30T17:23:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bosulif-pfizer-mild-cognitive-impairment-likelihood-of-approval/ 2024-12-30T17:23:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-bristol-myers-squibb-refractory-multiple-myeloma-likelihood-of-approval/ 2024-12-30T17:23:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regorafenib-bayer-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T17:23:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/niraparib-gsk-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-30T17:23:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orticumab-abcentra-inflammation-likelihood-of-approval/ 2024-12-30T17:23:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/entinostat-taizhou-yiteng-jingang-pharmaceutical-solid-tumor-likelihood-of-approval/ 2024-12-30T17:23:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/darleukin-philogen-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T17:23:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orticumab-abcentra-acute-coronary-syndrome-likelihood-of-approval/ 2024-12-30T17:23:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avutometinib-potassium-verastem-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-12-30T17:23:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-bristol-myers-squibb-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T17:23:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-12-30T17:23:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tbo-309-thrombio-holdings-acute-ischemic-stroke-likelihood-of-approval/ 2024-12-30T17:22:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-bristol-myers-squibb-gliosarcoma-likelihood-of-approval/ 2024-12-30T17:22:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/niraparib-gsk-endometrial-cancer-likelihood-of-approval/ 2024-12-30T17:22:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anumigilimab-csl-sickle-cell-disease-likelihood-of-approval/ 2024-12-30T17:22:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acotiamide-hydrochloride-zeria-pharmaceutical-functional-non-ulcer-dyspepsia-likelihood-of-approval/ 2024-12-30T17:22:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-gastric-cancer-likelihood-of-approval/ 2024-12-30T17:22:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-bristol-myers-squibb-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-12-30T17:22:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cep-11981-teva-pharmaceutical-industries-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-30T17:22:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cep-11981-teva-pharmaceutical-industries-adenocarcinoma-likelihood-of-approval/ 2024-12-30T17:22:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2024-12-30T17:22:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-fallopian-tube-cancer-likelihood-of-approval/ 2024-12-30T17:22:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blarcamesine-hydrochloride-anavex-life-sciences-angelman-syndrome-likelihood-of-approval/ 2024-12-30T17:22:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lutetium-lu-177-dotatate-curium-midco-neuroendocrine-gastroenteropancreatic-tumors-gep-net-likelihood-of-approval/ 2024-12-30T17:21:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dkfma-102-dongkook-pharmaceutical-prostate-cancer-likelihood-of-approval/ 2024-12-30T17:21:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ebv-specific-anti-pd1-tcr-t-cells-tcr-cure-biopharma-technology-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2024-12-30T17:21:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bd-113-shanghai-bdgene-therapeutics-open-angle-glaucoma-likelihood-of-approval/ 2024-12-30T17:21:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fth-002-faeth-therapeutics-rectal-cancer-likelihood-of-approval/ 2024-12-30T17:21:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sapanisertib-serabelisib-faeth-therapeutics-solid-tumor-likelihood-of-approval/ 2024-12-30T17:21:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abo-2015-suzhou-abogen-biosciences-hematological-tumor-likelihood-of-approval/ 2024-12-30T17:21:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07934040-pfizer-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-12-30T17:21:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07934040-pfizer-colorectal-cancer-likelihood-of-approval/ 2024-12-30T17:21:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/angiotensin-ii-platform-therapeutics-muscle-spasm-likelihood-of-approval/ 2024-12-30T17:21:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pank-003-first-condor-group-solid-tumor-likelihood-of-approval/ 2024-12-30T17:21:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ev68-228-n-kbio-flaccid-paralysis-likelihood-of-approval/ 2024-12-30T17:20:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgc-515-bridgene-biosciences-malignant-mesothelioma-likelihood-of-approval/ 2024-12-30T17:20:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgc-515-bridgene-biosciences-solid-tumor-likelihood-of-approval/ 2024-12-30T17:20:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apl-5125-apollo-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T17:20:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apl-5125-apollo-therapeutics-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2024-12-30T17:20:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apl-5125-apollo-therapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T17:20:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apl-5125-apollo-therapeutics-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-30T17:20:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apl-5125-apollo-therapeutics-endometrial-cancer-likelihood-of-approval/ 2024-12-30T17:20:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apl-5125-apollo-therapeutics-gastric-cancer-likelihood-of-approval/ 2024-12-30T17:20:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apl-5125-apollo-therapeutics-prostate-cancer-likelihood-of-approval/ 2024-12-30T17:20:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apl-5125-apollo-therapeutics-ovarian-cancer-likelihood-of-approval/ 2024-12-30T17:20:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sir-2501-sironax-neuropathy-likelihood-of-approval/ 2024-12-30T17:20:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sir-2501-sironax-neurodegenerative-diseases-likelihood-of-approval/ 2024-12-30T17:20:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apl-4098-apollo-therapeutics-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T17:19:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apl-4098-apollo-therapeutics-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-30T17:19:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apl-4098-apollo-therapeutics-refractory-anemia-with-excess-blasts-likelihood-of-approval/ 2024-12-30T17:19:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apl-4098-apollo-therapeutics-myelodysplastic-syndrome-likelihood-of-approval/ 2024-12-30T17:19:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-88998377-johnson-johnson-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-30T17:19:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denosumab-biosimilar-meitheal-pharmaceuticals-bone-metastasis-likelihood-of-approval/ 2024-12-30T17:19:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mt-303-myeloid-therapeutics-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2024-12-30T17:19:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lat-010-latticon-antibody-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T17:19:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lat-010-latticon-antibody-therapeutics-renal-cell-carcinoma-likelihood-of-approval/ 2024-12-30T17:19:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lat-010-latticon-antibody-therapeutics-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-30T17:19:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lat-010-latticon-antibody-therapeutics-gastric-cancer-likelihood-of-approval/ 2024-12-30T17:19:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lat-010-latticon-antibody-therapeutics-melanoma-likelihood-of-approval/ 2024-12-30T17:18:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lat-010-latticon-antibody-therapeutics-colorectal-cancer-likelihood-of-approval/ 2024-12-30T17:17:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lat-010-latticon-antibody-therapeutics-ovarian-cancer-likelihood-of-approval/ 2024-12-30T17:17:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lat-010-latticon-antibody-therapeutics-breast-cancer-likelihood-of-approval/ 2024-12-30T17:16:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ix-001-immuxell-biotech-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T16:56:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trx-103-tr1x-graft-versus-host-disease-gvhd-likelihood-of-approval/ 2024-12-30T16:56:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kite-197-kite-pharma-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T16:56:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ix-001-immuxell-biotech-colorectal-cancer-likelihood-of-approval/ 2024-12-30T16:56:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-0174-antido-therapeutics-australia-non-small-cell-lung-carcinoma-likelihood-of-approval/ 2024-12-30T16:56:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-0174-antido-therapeutics-australia-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-30T16:56:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-0174-antido-therapeutics-australia-peritoneal-cancer-likelihood-of-approval/ 2024-12-30T16:56:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-0174-antido-therapeutics-australia-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-12-30T16:56:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-0174-antido-therapeutics-australia-fallopian-tube-cancer-likelihood-of-approval/ 2024-12-30T16:55:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-0174-antido-therapeutics-australia-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2024-12-30T16:55:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-0174-antido-therapeutics-australia-oligodendroglioma-likelihood-of-approval/ 2024-12-30T16:55:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-0174-antido-therapeutics-australia-thyroid-cancer-likelihood-of-approval/ 2024-12-30T16:55:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-0174-antido-therapeutics-australia-anaplastic-astrocytoma-likelihood-of-approval/ 2024-12-30T16:55:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-0174-antido-therapeutics-australia-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-30T16:55:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-0174-antido-therapeutics-australia-solid-tumor-likelihood-of-approval/ 2024-12-30T16:55:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-0174-antido-therapeutics-australia-endometrial-cancer-likelihood-of-approval/ 2024-12-30T16:55:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-0174-antido-therapeutics-australia-melanoma-likelihood-of-approval/ 2024-12-30T16:55:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-0174-antido-therapeutics-australia-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T16:55:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inca-33890-incyte-solid-tumor-likelihood-of-approval/ 2024-12-30T16:55:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bezafibrate-obeticholic-acid-intercept-pharmaceuticals-primary-biliary-cholangitis-primary-biliary-cirrhosis-likelihood-of-approval/ 2024-12-30T16:55:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qtx-3046-quanta-therapeutics-solid-tumor-likelihood-of-approval/ 2024-12-30T16:55:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qtx-3046-quanta-therapeutics-endometrial-cancer-likelihood-of-approval/ 2024-12-30T16:55:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivw-1001-iview-therapeutics-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/ 2024-12-30T16:55:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/db-1311-biontech-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-30T16:55:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/a-103-tcr-cure-biopharma-technology-solid-tumor-likelihood-of-approval/ 2024-12-30T16:54:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/a-103-tcr-cure-biopharma-technology-testicular-cancer-likelihood-of-approval/ 2024-12-30T16:54:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jcxh-108-immorna-hangzhou-biotechnology-respiratory-syncytial-virus-rsv-infections-likelihood-of-approval/ 2024-12-30T16:54:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/a-103-tcr-cure-biopharma-technology-lung-cancer-likelihood-of-approval/ 2024-12-30T16:54:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-6793-astrazeneca-chronic-obstructive-pulmonary-disease-copd-likelihood-of-approval/ 2024-12-30T16:54:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alia-1758-aliada-therapeutics-alzheimer-s-disease-likelihood-of-approval/ 2024-12-30T16:54:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/coronavirus-disease-2019-covid-19-influenza-vaccine-pfizer-influenzavirus-a-infections-likelihood-of-approval/ 2024-12-30T16:54:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/coronavirus-disease-2019-covid-19-influenza-vaccine-pfizer-influenzavirus-b-infections-likelihood-of-approval/ 2024-12-30T16:54:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acdn-01-ascidian-therapeutics-juvenile-macular-degeneration-stargardt-disease-likelihood-of-approval/ 2024-12-30T16:54:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acdn-01-ascidian-therapeutics-retinopathy-likelihood-of-approval/ 2024-12-30T16:54:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rabies-vaccine-astrivax-rabies-likelihood-of-approval/ 2024-12-30T16:54:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/caba-201-cabaletta-bio-systemic-sclerosis-scleroderma-likelihood-of-approval/ 2024-12-30T16:54:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gemcitabine-sr-sustained-therapeutics-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2024-12-30T16:54:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avx-70120-astrivax-yellow-fever-likelihood-of-approval/ 2024-12-30T16:54:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ray-121-chugai-pharmaceutical-immune-mediated-necrotizing-myopathy-imnm-likelihood-of-approval/ 2024-12-30T16:54:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trx-221-therapex-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T16:54:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ray-121-chugai-pharmaceutical-idiopathic-thrombocytopenic-purpura-immune-thrombocytopenic-purpura-likelihood-of-approval/ 2024-12-30T16:53:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ray-121-chugai-pharmaceutical-dermatomyositis-likelihood-of-approval/ 2024-12-30T16:53:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ray-121-chugai-pharmaceutical-antiphospholipid-syndrome-likelihood-of-approval/ 2024-12-30T16:53:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ray-121-chugai-pharmaceutical-behcet-disease-likelihood-of-approval/ 2024-12-30T16:53:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-151128-shionogi-osteoarthritis-likelihood-of-approval/ 2024-12-30T16:53:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ray-121-chugai-pharmaceutical-bullous-pemphigoid-likelihood-of-approval/ 2024-12-30T16:53:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/revtx-300-revelation-biosciences-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2024-12-30T16:53:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/idrx-42-idrx-gastrointestinal-stromal-tumor-gist-likelihood-of-approval/ 2024-12-30T16:53:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mdx-2001-modex-therapeutics-uterine-cancer-likelihood-of-approval/ 2024-12-30T16:53:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/m-9140-merck-solid-tumor-likelihood-of-approval/ 2024-12-30T16:53:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mdx-2001-modex-therapeutics-solid-tumor-likelihood-of-approval/ 2024-12-30T16:53:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mdx-2001-modex-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T16:53:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mdx-2001-modex-therapeutics-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T16:53:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mdx-2001-modex-therapeutics-gastric-cancer-likelihood-of-approval/ 2024-12-30T16:53:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mdx-2001-modex-therapeutics-prostate-cancer-likelihood-of-approval/ 2024-12-30T16:52:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mdx-2001-modex-therapeutics-colon-cancer-likelihood-of-approval/ 2024-12-30T16:52:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pit-565-novartis-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T16:52:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pit-565-novartis-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-12-30T16:52:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pit-565-novartis-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T16:52:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pit-565-novartis-follicular-lymphoma-likelihood-of-approval/ 2024-12-30T16:52:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/thrv-1268-thryv-therapeutics-atrial-fibrillation-likelihood-of-approval/ 2024-12-30T16:52:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/thrv-1268-thryv-therapeutics-diastolic-heart-failure-hfpef-likelihood-of-approval/ 2024-12-30T16:52:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vls-1488-volastra-therapeutics-peritoneal-cancer-likelihood-of-approval/ 2024-12-30T16:52:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asp-3082-astellas-pharma-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T16:52:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sy-201-seinda-pharmaceutical-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/ 2024-12-30T16:52:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vls-1488-volastra-therapeutics-fallopian-tube-cancer-likelihood-of-approval/ 2024-12-30T16:52:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jcxh-211-immorna-hangzhou-biotechnology-solid-tumor-likelihood-of-approval/ 2024-12-30T16:52:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hrs-8427-jiangsu-hengrui-medicine-pyelonephritis-likelihood-of-approval/ 2024-12-30T16:52:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aps-03118-applied-pharmaceutical-science-medullary-thyroid-cancer-likelihood-of-approval/ 2024-12-30T16:52:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aps-03118-applied-pharmaceutical-science-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T16:52:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prj-13024-guangzhou-yinming-biomedical-technology-metastatic-melanoma-likelihood-of-approval/ 2024-12-30T16:51:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abi-5366-assembly-biosciences-genital-herpes-likelihood-of-approval/ 2024-12-30T16:51:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsn-084-tyligand-biotechnology-shanghai-gastric-cancer-likelihood-of-approval/ 2024-12-30T16:51:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prj-13024-guangzhou-yinming-biomedical-technology-colon-cancer-likelihood-of-approval/ 2024-12-30T16:51:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mtx-101-mozart-therapeutics-celiac-disease-likelihood-of-approval/ 2024-12-30T16:51:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203cd8-immatics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-30T16:51:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-vibostolimab-merck-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T16:51:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mtx-101-mozart-therapeutics-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/ 2024-12-30T16:51:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046048-pfizer-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-12-30T16:51:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046048-pfizer-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-30T16:51:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046048-pfizer-fallopian-tube-cancer-likelihood-of-approval/ 2024-12-30T16:51:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046048-pfizer-peritoneal-cancer-likelihood-of-approval/ 2024-12-30T16:51:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prt-3645-prelude-therapeutics-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-30T16:51:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cusp-06-oncusp-therapeutics-renal-cell-carcinoma-likelihood-of-approval/ 2024-12-30T16:51:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prt-3645-prelude-therapeutics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-30T16:51:08+00:00 daily 0.2